Modality
siRNA
MOA
JAK1/2i
Target
CDK2
Pathway
Autophagy
OCDNB
Development Pipeline
Preclinical
~Jul 2013
→ ~Oct 2014
Phase 1
~Jan 2015
→ ~Apr 2016
Phase 2
~Jul 2016
→ ~Oct 2017
Phase 3
Jan 2018
→ Aug 2028
Phase 3Current
NCT05766348
330 pts·OCD
2024-12→2028-08·Terminated
NCT03286910
2,762 pts·NB
2024-02→2028-06·Completed
NCT08803535
357 pts·NB
2018-01→2025-10·Terminated
+1 more trial
4,509 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-10-205mo agoPh3 Readout· NB
2027-08-061.3y awayPh3 Readout· OCD
2028-06-122.2y awayPh3 Readout· NB
2028-08-102.4y awayPh3 Readout· OCD
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Termina…
P3
Complet…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2025-10-20 · 5mo ago
NB
Ph3 Readout
2027-08-06 · 1.3y away
OCD
Ph3 Readout
2028-06-12 · 2.2y away
NB
Ph3 Readout
2028-08-10 · 2.4y away
OCD
CompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05766348 | Phase 3 | OCD | Terminated | 330 | ORR |
| NCT03286910 | Phase 3 | NB | Completed | 2762 | DAS28 |
| NCT08803535 | Phase 3 | NB | Terminated | 357 | VA |
| NCT06203355 | Phase 3 | OCD | Completed | 1060 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |